United States Patent and Trademark Office awards Immatics patent for innovative immunotherapies
FREDERICK, Md. (January 3, 2019) – McBee, Moore, Woodward and Vanik IP, LLC (MMWV Law) is proud to announce that the United States Patent and Trademark Office has awarded MMWV Law’s client Immatics Biotechnologies GmBH (Immatics), a leading company in the field of immunotherapy, its 100th U.S. patent.
In a press release issued earlier today, Immatics indicated thatImmatics’ 100th patent (US Patent No. 10,143,731) demonstrates a significant achievement in innovation in the Life Sciences industry. Using the Company’s XPRESIDENT® technology, Immatics identified a peptide presented on the human leucocyte antigen (HLA), a key piece to the development of cancer immunotherapies.
“We are thrilled to have the opportunity to be on Immatics’ IP team for over 10 years,” stated Susan McBee, the Managing Partner of McBee, Moore, Woodward & Vanik IP, LLC. “This is an exciting time, given all the developments in this technology space. We have developed an approach to sufficiently cover Immatics’ products and methods while still meeting the patentability requirements in the USA in an ever-changing field. The number of granted patents to Immatics has reached 116 this week and we are working hard to further enhance the protection for Immatics to help them to bring a cure for cancer to patients.”
It is the goal of Immatics and MMWV Law to provide a strategy that ensures broad protection of Immatics’ products, technologies and methods while meeting the requirements of the United States in a highly competitive industry.